Complications Management Flashcards
7 cards from real BC ADM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Complications Management flashcards as text
A patient with T2DM presents with an eGFR of 28 mL/min/1.73m². Which medication should be discontinued to prevent lactic acidosis?
Answer: Metformin
Metformin is contraindicated when eGFR falls below 30 mL/min/1.73m² due to the risk of lactic acidosis from drug accumulation.
Which finding on monofilament testing indicates loss of protective sensation in the diabetic foot?
Answer: Inability to feel the 10-g Semmes-Weinstein monofilament
Inability to detect the 10-g monofilament at plantar sites indicates loss of protective sensation and high ulcer risk.
A patient with proliferative diabetic retinopathy is started on which first-line intravitreal treatment to reduce neovascularization?
Answer: Anti-VEGF agents
Anti-VEGF agents (e.g., ranibizumab, aflibercept) are first-line for proliferative diabetic retinopathy and diabetic macular edema.
Which autonomic neuropathy manifestation most directly increases the risk of silent myocardial infarction in diabetic patients?
Answer: Cardiac autonomic neuropathy causing reduced pain perception
Cardiac autonomic neuropathy impairs pain signaling, allowing myocardial infarctions to occur without typical chest pain.
A patient with diabetic nephropathy has a urine albumin-to-creatinine ratio of 450 mg/g. Which drug class is indicated to slow progression?
Answer: SGLT2 inhibitors
SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin) have proven renoprotective effects independent of glucose lowering in CKD with albuminuria.
Which stage of Charcot neuroarthropathy is characterized by active bone destruction, warmth, and erythema without deformity?
Answer: Eichenholtz Stage 1 (Development)
Eichenholtz Stage 1 (Development) features acute inflammation, bone fragmentation, and joint dislocation without established deformity.
In a patient with diabetic peripheral neuropathy experiencing burning pain, which first-line pharmacological agent is recommended by ADA guidelines?
Answer: Duloxetine
Duloxetine (SNRI) is an ADA-recommended first-line agent for painful diabetic peripheral neuropathy with good evidence for efficacy.